# US 2024/0200029 A1 · Nkp30 receptor targeted therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200029 A1
- Document ID: US20240200029A1
- Status: Published application
- Kind: A1
- Application number: 18/513,960
- Filed: 2023-11-20
- Published: 2024-06-20
- Earliest claimed: 2011-08-31
- Assignees: Trustees of Dartmouth College
- Applicants: The Trustees of Dartmouth College
- Inventors: Tong ZHANG; Charles L. SENTMAN
- Web page: https://patentgrep.com/patent/US20240200029A1

## CPC

- C07K 14/70503: {Immunoglobulin superfamily}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61P 35/00: Antineoplastic agents
- C07K 14/70521: {CD28, CD152}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0636: {T lymphocytes}
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/03: containing a transmembrane segment
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells to address diseases and disorders. In one aspect, the disclosure broadly relates to chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.

## Claims

### Claim at position 1

1-394. (canceled)

### Claim 395

A nucleic acid construct that encodes a chimeric receptor, or a cell containing said nucleic acid construct, wherein said nucleic acid construct comprises a promoter operably linked to a nucleic acid sequence that encodes a chimeric NKp30 receptor comprising an NKp30 extracellular domain, a transmembrane domain, and at least one signaling domain, wherein (i) said transmembrane domain comprises a transmembrane domain of a polypeptide selected from the group consisting of NKp30, CD28, CD8, CD3ζ, CD27, 41BB, OX40, and DAP12, and (ii) said at least one signaling domain comprises a signaling domain of a polypeptide selected from the group consisting of NKp30, CD28, CD8, CD31w DAP10, CD27, 41BB, OX40, and DAP12, wherein at least one transmembrane (TM) domain or at least one signaling domain is from a polypeptide other than NKp30.

### Claim 396 (depends on 395)

A chimeric polypeptide encoded by the nucleic acid construct of claim 395.

### Claim 397 (depends on 395)

A T cell or a T cell progenitor which comprises a nucleic acid construct according to claim 395.

### Claim 398 (depends on 396)

A method of treating cancer in a subject in need thereof comprising administering a T cell or T cell progenitor which expresses a chimeric polypeptide according to claim 396, optionally wherein the treated cancer is selected from leukemia, lymphoma, myeloma, cervical cancer, ovarian cancer, gastric sarcoma, breast cancer, pancreatic cancer, melanoma, colorectal cancer and prostate cancer.

### Claim 399 (depends on 396)

A method of treating a disease involving dendritic cells in a subject in need thereof comprising administering a T cell or T cell progenitor which expresses a chimeric polypeptide according to claim 396, thereby activating an anti-dendritic cell response in the patient, optionally wherein the disease involving dendritic cells is an autoimmune disease, further optionally selected from arthritis, lupus, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or the disease comprises transplant rejection or graft versus host disease.

### Claim 400 (depends on 398)

The method of claim 398 wherein the chimeric polypeptide comprises (i) a NKp30 extracellular domain, a CD28 transmembrane (TM) domain, a CD28 signaling domain, and a CD3ζ signaling domain; (ii) a chimeric NKp30-CD28-CD3ζ receptor comprising the amino acid sequence of SEQ ID NO:61; (iii) a NKp30 extracellular domain, a CD3ζ transmembrane domain, and a CD3ζ signaling domain; (iv) a chimeric NKp30-CD3K receptor comprising the amino acid sequence of SEQ ID NO:60; (v) a NKp30 extracellular domain, a CD28 transmembrane (TM) domain, a DAP10 signaling domain, and a CD3ζ signaling domain; (vi) a chimeric NKp30-CD28(TM)-DAP10-CD3ζ receptor comprising the amino acid sequence of SEQ ID NO: 65; (vii) a NKp30 extracellular domain, a CD28 transmembrane (TM) domain, a DAP10 signaling domain, and a CD3ζ signaling domain; (viii) a chimeric NKp30-CD28(TM)-CD3ζ-DAP10 receptor comprising the amino acid sequence of SEQ ID NO: 67; (ix) a NKp30 extracellular domain, a CD28 transmembrane (TM) domain, a CD27 signaling domain, and a CD3ζ signaling domain; (x) a chimeric NKp30-CD28(TM)-CD27-CD3ζ receptor comprising the amino acid sequence of SEQ ID NO: 69; (xi) a NKp30 extracellular domain, a CD28 transmembrane (TM) domain, and a CD3ζ signaling domain; (xii) a chimeric NKp30-CD28(TM)-CD3ζ receptor comprising the amino add sequence of SEQ ID NO: 62; (xiii) a NKp30 extracellular domain, a CD8 transmembrane (TM) domain, and a CD3ζ signaling domain; or (xiv) a chimeric NKp30-CD8(TM)-CD3ζ receptor comprising the amino acid sequence of SEQ ID NO: 63.

### Claim 401 (depends on 399)

The method of claim 399, wherein the chimeric polypeptide comprises (i) a NKp30 extracellular domain, a CD28 transmembrane (TM) domain, a CD28 signaling domain, and a CD3ζ signaling domain; (ii) a chimeric NKp30-CD28-CD3ζ receptor comprising the amino acid sequence of SEQ ID NO:61; (iii) a NKp30 extracellular domain, a CD3ζ transmembrane domain, and a CD3ζ signaling domain; (iv) a chimeric NKp30-CD3K receptor comprising the amino acid sequence of SEQ ID NO:60; (v) a NKp30 extracellular domain, a CD28 transmembrane (TM) domain, a DAP10 signaling domain, and a CD3ζ signaling domain; (vi) a chimeric NKp30-CD28(TM)-DAP10-CD3ζ receptor comprising the amino acid sequence of SEQ ID NO: 65; (vii) a NKp30 extracellular domain, a CD28 transmembrane (TM) domain, a DAP10 signaling domain, and a CD3ζ signaling domain; (viii) a chimeric NKp30-CD28(TM)-CD3ζ-DAP10 receptor comprising the amino acid sequence of SEQ ID NO: 67; (ix) a NKp30 extracellular domain, a CD28 transmembrane (TM) domain, a CD27 signaling domain, and a CD3ζ signaling domain; (x) a chimeric NKp30-CD28(TM)-CD27-CD3ζ receptor comprising the amino acid sequence of SEQ ID NO: 69; (xi) a NKp30 extracellular domain, a CD28 transmembrane (TM) domain, and a CD3ζ signaling domain; (xii) a chimeric NKp30-CD28(TM)-CD3ζ receptor comprising the amino add sequence of SEQ ID NO: 62; (xiii) a NKp30 extracellular domain, a CD8 transmembrane (TM) domain, and a CD3ζ signaling domain; or (xiv) a chimeric NKp30-CD8(TM)-CD3ζ receptor comprising the amino acid sequence of SEQ ID NO: 63.

### Claim 402 (depends on 398)

The method of claim 398, wherein the administered T cell or T cell progenitor comprises a nucleic acid construct which encodes (i) a chimeric NKp30-CD3ζ receptor, said nucleic acid construct comprising the nucleic acid sequence of SEQ ID NO:124; (iii) a chimeric NKp30-CD28(TM)-CD3ζ-DAP10 receptor, said nucleic acid construct comprising the nucleic acid sequence of SEQ ID NO:66; (iv) a chimeric NKp30-CD28(TM)-CD27-CD3ζ receptor, said nucleic acid construct comprising the nucleic acid sequence of SEQ ID NO: 68; (v) a chimeric NKp30-CD8(TM)-CD3ζ receptor, said nucleic acid construct comprising the nucleic acid sequence or SEQ ID NO: 127; (vi) a chimeric NKp30-CD28-CD3ζ receptor, said nucleic acid construct comprising the nucleic acid sequence of SEQ ID NO:125; or (vii) a chimeric NKp30-CD28(TM)-CD3ζ receptor, said nucleic acid construct comprising the nucleic acid sequence of SEQ ID NO: 126.

### Claim 403 (depends on 399)

The method of claim 399, wherein the administered T cell or T cell progenitor comprises a nucleic acid construct which encodes (i) a chimeric NKp30-CD3K receptor, said nucleic acid construct comprising the nucleic acid sequence of SEQ ID NO:124; (iii) a chimeric NKp30-CD28(TM)-CD3ζ-DAP10 receptor, said nucleic acid construct comprising the nucleic acid sequence of SEQ ID NO:66; (iv) a chimeric NKp30-CD28(TM)-CD27-CD3ζ receptor, said nucleic acid construct comprising the nucleic acid sequence of SEQ ID NO: 68; (v) a chimeric NKp30-CD8(TM)-CD3ζ receptor, said nucleic acid construct comprising the nucleic acid sequence or SEQ ID NO: 127; (vi) a chimeric NKp30-CD28-CD3ζ receptor, said nucleic acid construct comprising the nucleic acid sequence of SEQ ID NO:125; or (vii) a chimeric NKp30-CD28(TM)-CD3ζ receptor, said nucleic acid construct comprising the nucleic acid sequence of SEQ ID NO: 126.

### Claim 404 (depends on 398)

The method of claim 398, wherein the administered T cell or T cell progenitor comprises a primary human T cell.

### Claim 405 (depends on 399)

The method of claim 399, wherein the administered T cell or T cell progenitor comprises a primary human T cell.

### Claim 406 (depends on 398)

The method of claim 398, wherein the chimeric polypeptide expressed by the administered T cell or T cell progenitor further comprises an additional signaling domain comprising a signaling domain of a polypeptide selected from the group consisting of NKp30, CD28, CD8, CD31, DAP10, CD27, 41BB, OX40, and DAP12.

### Claim 407 (depends on 399)

The method of claim 399, wherein the chimeric polypeptide expressed by the administered T cell or T cell progenitor further comprises an additional signaling domain comprising a signaling domain of a polypeptide selected from the group consisting of NKp30, CD28, CD8, CD3ζ, DAP10, CD27, 41BB, OX40, and DAP12.

### Claim 408 (depends on 398)

The method of claim 398, wherein the chimeric polypeptide expressed by the administered T cell or T cell progenitor comprises at least one of the following: (i) a NKp30 extracellular domain as shown in FIG. 16, FIG. 17, FIG. 18, FIG. 20, FIG. 21, or FIG. 22; (ii) a CD3ζ transmembrane (TM) domain as shown in FIG. 16; (iii) a CD28 transmembrane (TM) domain as shown in FIG. 18, FIG. 20, FIG. 21, or FIG. 22; (iv) a CD3ζ signaling domain that comprises the CD3ζ cytoplasmic domain as shown in FIG. 18, FIG. 20, FIG. 21, or FIG. 22; (v) a DAP10 signaling domain that comprises the DAP10 cytoplasmic domain as shown in FIG. 20 or FIG. 21; or (vi) a CD27 signaling domain that comprises the CD27 cytoplasmic domain shown in FIG. 22.

### Claim 409 (depends on 399)

The method of claim 399, wherein the chimeric polypeptide expressed by the administered T cell or T cell progenitor comprises at least one of the following: (i) a NKp30 extracellular domain as shown in FIG. 16, FIG. 17, FIG. 18, FIG. 20, FIG. 21, or FIG. 22; (ii) a CD3ζ transmembrane (TM) domain as shown in FIG. 16; (iii) a CD28 transmembrane (TM) domain as shown in FIG. 18, FIG. 20, FIG. 21, or FIG. 22; (iv) a CD3ζ signaling domain that comprises the CD3ζ cytoplasmic domain as shown in FIG. 18, FIG. 20, FIG. 21, or FIG. 22; (v) a DAP10 signaling domain that comprises the DAP10 cytoplasmic domain as shown in FIG. 20 or FIG. 21; or (vi) a CD27 signaling domain that comprises the CD27 cytoplasmic domain shown in FIG. 22.

### Claim 410 (depends on 398)

The method of claim 398, wherein the administered T cell or T cell progenitor further comprises a suicide gene.

### Claim 411 (depends on 399)

The method of claim 399, wherein the administered T cell or T cell progenitor further comprises a suicide gene.

### Claim 412 (depends on 398)

The method of claim 398, wherein the administered T cell or T cell progenitor is a TCR-deficient T cell.

### Claim 413 (depends on 399)

The method of claim 399, wherein the administered T cell or T cell progenitor is a TCR-deficient T cell.
